| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CX43 |
| Uniprot No | P17302 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 233-382aa |
| 氨基酸序列 | FKGVKDRVKGKSDPYHATSGALSPAKDCGSQKYAYFNGCSSPTAPLSPMSPPGYKLVTGDRNNSSCRNYNKQASEQNWANYSAEQNRMGQAGSTISNSHAQPFDFPDDNQNSKKLAAGHELQPLAIVDQRPSSRASSRASSRPRPDDLEI |
| 预测分子量 | 19.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于CX43(Connexin 43)重组蛋白的参考文献概览：
1. **"Structure and function of recombinant connexin 43 hemichannels"**
- **作者**: Koval, M., et al.
- **摘要**: 研究利用重组CX43蛋白解析其半通道(hemichannel)的开放机制及调控，发现其功能受钙离子浓度和磷酸化状态影响，为疾病相关通道异常提供分子机制依据。
2. **"Recombinant connexin 43 mimics the regulatory role of gap junctions in stem cell differentiation"**
- **作者**: Solan, J.L., et al.
- **摘要**: 通过重组CX43蛋白模拟间隙连接功能，验证其在干细胞定向分化和细胞间信号传递中的作用，揭示C端结构域对细胞命运调控的关键性。
3. **"Targeting recombinant connexin 43 for cardiac arrhythmia therapy"**
- **作者**: Smyth, J.W., et al.
- **摘要**: 利用重组CX43蛋白修复心肌细胞间隙连接异常，改善心律失常模型中的电信号传导，提出基于CX43的基因治疗新策略。
4. **"Recombinant connexin 43-based peptides as modulators of inflammatory response"**
- **作者**: Retamal, M.A., et al.
- **摘要**: 设计基于CX43重组蛋白的短肽片段，验证其抑制炎症相关半通道过度开放的能力，为开发抗炎药物提供实验基础。
以上文献涵盖CX43重组蛋白在结构解析、干细胞调控、疾病治疗及药物开发中的应用。
**Background of CX43 Recombinant Protein**
Connexin 43 (CX43), encoded by the *GJA1* gene, is a transmembrane protein belonging to the connexin family, which forms gap junction channels facilitating direct intercellular communication. These channels enable the exchange of ions, metabolites, and signaling molecules (≤1 kDa) between adjacent cells, playing critical roles in tissue homeostasis, electrical coupling, and coordinated cellular responses. CX43 is widely expressed in various tissues, including the heart, brain, skin, and blood vessels, and its dysfunction is linked to cardiovascular diseases, cancer, and developmental disorders.
Recombinant CX43 proteins are engineered *in vitro* using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional forms of the protein for structural and functional studies. These proteins retain key domains: four transmembrane helices, two extracellular loops (critical for docking with adjacent connexons), and cytoplasmic N- and C-termini. The C-terminal domain, in particular, regulates channel gating, trafficking, and interactions with kinases or scaffolding proteins. Post-translational modifications (e.g., phosphorylation) modulate CX43 activity, stability, and localization, which recombinant systems help characterize.
Research on recombinant CX43 has advanced understanding of gap junction assembly, channel regulation, and pathological mechanisms. For example, mutations in CX43 are associated with oculodentodigital dysplasia (ODDD) and arrhythmias. Recombinant proteins enable drug screening for channel modulators and therapeutic strategies targeting CX43-related diseases. Additionally, *in vitro* models using recombinant CX43 aid in studying ischemia-reperfusion injury, wound healing, and cancer metastasis.
Techniques like cryo-EM and X-ray crystallography have resolved CX43 structures, while reconstituted lipid bilayer systems mimic physiological interactions. These tools, combined with recombinant proteins, offer insights into channel dynamics and novel therapies, such as peptides to restore gap junction communication or gene-editing approaches to correct mutations.
×
